Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING

Targeted Therapy to Increase RAI Uptake in Metastatic DTC

NCT05024929 · View on ClinicalTrials.gov ↗

Study Summary

Papillary thyroid cancer (PTC) is a common type of differentiated thyroid cancer (DTC) in children and represents the second most common cancer in adolescent females. Recently targeted drugs that block many of the genetic drivers of DTC have become available. While Investigators know that these drugs shrink DTC tumors in many cases, the impact on radioactive iodine (RAI) avidity has not been systematically studied.

Interventions

  • PROCEDURE Whole body scan

Study Locations (9)

Texas

  • MD Anderson Cancer Center — Houston
  • Texas Children's Hospital — Houston

California

  • University of California San Francisco — San Francisco

Georgia

  • Emory University School of Medicine — Atlanta

Massachusetts

  • Boston Children's Hospital — Boston

Pennsylvania

  • Children's Hospital of Philadelphia — Philadelphia

Tennessee

  • St. Jude Children's Research Hospital — Memphis

Washington

  • Seattle Children's Hospital — Seattle

New South Wales

  • Children's Hospital Westmead — Sydney

Trial Details

FieldValue
Enrollment Target 32 participants
Start Date 2021-07-16
Est. Completion 2033-02-01

Sponsor

Children's Hospital of Philadelphia

492 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05024929

The ClinicalTrials.gov registry entry for NCT05024929 describes a study currently listed as recruiting. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Children's Hospital of Philadelphia, which has 492 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 3 conditions, with Pediatric Cancer appearing as the primary indexed condition, and to 1 intervention — of which Whole body scan is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT05024929 reports 9 study locations spanning 8 distinct geographic areas — top geographies include Texas, California, Georgia. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT05024929 about?

NCT05024929 is a clinical study titled "Targeted Therapy to Increase RAI Uptake in Metastatic DTC". Papillary thyroid cancer (PTC) is a common type of differentiated thyroid cancer (DTC) in children and represents the second most common cancer in adolescent females. Recently targeted drugs that block many of the genetic drivers of DTC have become available. While Investigators know that these drug...

What is the current status of trial NCT05024929?

This trial is currently recruiting. The enrollment target is 32 participants. The study started on 2021-07-16. Estimated completion is 2033-02-01.

What conditions does trial NCT05024929 study?

This clinical trial studies the following conditions: Pediatric Cancer, Papillary Thyroid Cancer, Differentiated Thyroid Cancer. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT05024929?

The interventions under investigation include: Whole body scan (PROCEDURE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT05024929?

This trial is sponsored by Children's Hospital of Philadelphia, which has 492 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT05024929 being conducted?

This trial has 9 study locations across California, Georgia, Massachusetts, Pennsylvania, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial